Antihypertensive drug interactions

Drugs of Today

Volumn 41, Issue 1, 2005, Pages 55-63

  Carter, Barry L ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALUMINUM; AMILORIDE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLOROTHIAZIDE; COLESTIPOL; DIGOXIN; DILTIAZEM; ENALAPRIL; FOSINOPRIL; GLIBENCLAMIDE; HERBACEOUS AGENT; IBUPROFEN; INDOMETACIN; INSULIN; ISRADIPINE; LISINOPRIL; LITHIUM; LIVER ENZYME; METHYLDOPA; METOPROLOL; MIBEFRADIL; PROPRANOLOL; QUINIDINE; TOLMETIN; UNINDEXED DRUG; VERAPAMIL;

CLINICAL TRIAL; COMORBIDITY; COMPUTER PROGRAM; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GERIATRIC CARE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PATIENT MONITORING; PHARMACIST; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICIAN; POLYPHARMACY; PRESCRIPTION; REVIEW; RISK REDUCTION;

ABSORPTION; ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; HUMANS; HYPERTENSION;

EID: 15344349579     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.1.875778     Document Type: Review

References (34)

1. Kelly, W.N. Potential risks and prevention, Part 1: Fatal adverse drug events. Am J Health Syst Pharm 2001, 58: 1317-24.
2. Kelly, W.N. Potential risks and prevention, Part 2: Drug-induced permanent disabilities. Am J Health Syst Pharm 2001, 58: 1325-9.
3. Marcellino, K., Kelly, W.N. Potential risks and prevention, Part 3: Drug-induced threats to life. Am J Health Syst Pharm 2001, 58: 1399-405.
4. Kelly, W.N. Potential risks and prevention, Part 4: Reports of significant adverse drug events. Am J Health Syst Pharm 2001, 58: 1406-12.
5. Kohn, L.T., Corrigan, J.M., Donaldson, M.S. To err is human: Building a safer health system. Institute of Medicine Committee on Quality of Healthcare in America: National Academy Press 1999.
6. Johnson, J.A., Bootman, J.L. Drug-related morbidity and mortality: A cost-of-illness model. Arch Intern Med 1995, 155: 1949-56.
7. Chrischilles, E.A., Segar, E.T., Wallace, R.B. Self-reported adverse drug reactions and related resource use. A study of community-dwelling persons 65 years of age and older. Ann Intern Med 1992, 117: 634-40.
8. Hanlon, J.T., Weinberger, M., Samsa, G.P. et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 1996, 100: 428-37.
9. Carter, B.L., Lund, B.C., Hayase, N., Chrischilles, E. The extent of potential antihypertensive drug interactions in a Medicaid population. Am J Hypertens 2002, 15: 953-7.
10. Carter, B.L., Lund, B.C., Hayase, N., Chrischilles, E. A longitudinal analysis of antihypertensive drug interactions in a Medicaid population. Am J Hypertens 2004, 17: 421-7.
11. Billups, S.J., Carter, B.L. Mibefradil: A new class of calcium-channel antagonist. Ann Pharmacother 1998, 32: 659-71.
12. Leahey, E.B., Jr., Reiffel, J.A., Drusin, R.E., Heissenbuttel, R.H., Lovejoy, W.P., Bigger, T. Interaction between quinidine and digoxin. JAMA 1978, 240: 533-4.
13. Bigger, J.T., Jr. The quinidine-digoxin interaction: What do we know about it? N Engl J Med 1979, 301: 779-81.
14. Drug interaction facts. Tatro, D.S. (Ed.). Facts and Comparisons, http://www.efactsweb.com/ DIF, accessed Oct. 8, 2004.
15. http://www.factsandcomparisons.com, accessed Oct. 8, 2004.
16. Drug interaction facts: Herbal supplements and food. Tatro, D.S. (Ed.). Facts and Comparisons. http://www.efactsweb.com/HIF, accessed Oct. 4, 2004.
17. Hansten, P.D., Horn, J.T. Drug interactions: Analysis and management. Tatro, D.S. (Ed.). Facts and Comparisons, St. Louis, Missouri 2003.
18. Chrischilles, E.A., Fulda, T.R., Bryns, P.J., Winkler, S.C., Rupp, M.T., Chui, M.A. The role of pharmacy computer systems in preventing medication errors. J Am Pharm Assoc 2002, 42: 439-48.
19. Chui, M.A., Rupp, MT. Evaluation of online prospective DUR programs in community pharmacy practice. J Managed Care Pharm 2000, 6: 27-32.
20. The U.S. Pharmacopoeia Drug Utilization Review Advisory Panel. Drug utilization review: Mechanisms to improve its effectiveness and broaden its scope. J Am Pharm Assoc 2000, 40: 538-45.
21. Campbell, N.R.C., Paddock, V., Sundarm, R. Alteration of methyldopa absorption, metabolism and blood pressure control caused by ferrous sulfate and ferrous gluconate. Clin Pharmacol Ther 1988, 43: 381-6.
22. Hunninghake, D.B., King, S., LaCroix, K. The effect of cholestryamine and colestipol on the absorption of hydrochlorothiazide. Int J Clin Pharmacol Ther Toxicol 1982, 20: 151-4.
23. Michalets, E.L. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998, 18: 84-112.
24. Kunzendorf, U., Walz, G., Brockmoeller, J. et al. Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation 1991, 52: 280-4.
25. Sketris, I.S., Methot, M.E., Nicol, D., Belitsky, P., Knox, M.G. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. Ann Pharmacother 1994, 28: 1227-31.
26. Eimer, M., Carter, B.L. Elevated serum carbamazepine concentrations following diltiazem initiation. Drug Intell Clin Pharm 1987, 21: 340-2.
27. Saseen, J.J., Carter, B.L. Dual calcium-channel blocker therapy in the treatment of hypertension. Ann Pharmacother 1996, 30: 802-10.
28. Saseen, J.J., Carter, B.L., Brown, T.E.R., Elliott, W.J., Black, H.R. Comparison of nifedipine alone and in combination with diltiazem or verapamil in hypertension. Hypertension 1996, 28: 109-14.
29. Klein, K.E., Lang, R., Weiss, E. et al. The influence of verapamil on serum digoxin concentrations. Circulation 1982, 65: 998-1003.
30. Kirimli, O., Kalkan, S., Guneri, S. et al. The effects of captopril on serum digoxin levels in patients with severe congestive heart failure, Int J Clin Pharmacol Ther 2001, 39: 311-4.
31. Johnson, A.G., Nguyen, T.V., Day, R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure: A meta-analysis. Ann Intern Med 1994, 121: 289-300.
32. Pope, J.E., Anderson, J.J., Felson, D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153: 477-84.
33. Gurwitz, J.H., Avorn, J., Bohn, R.L., Glynn, R.J., Monane, M., Mogun, H. Initiation of anti-hypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994, 272: 781-6.
34. Mansoor, G.A. Herbs and alternative therapies in the hypertension clinic. Am J Hypertens 2001, 14: 971-5.